☆ 4.6 Meeting Abstract

JDQ443, a covalent irreversible inhibitor of KRAS G12C, exhibits a novel binding mode and demonstrates potent anti-tumor activity and favorable pharmacokinetic properties in preclinical models

MOLECULAR CANCER THERAPEUTICS (2021)

Get Full Text
Add to Collection

Journal

MOLECULAR CANCER THERAPEUTICS
Volume 20, Issue 12, Pages -

Publisher

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1535-7163.TARG-21-P124

Keywords

-

Categories

Oncology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.